Search

Your search keyword '"Vigliotti, Maria Luigia"' showing total 2 results
Start Over Author "Vigliotti, Maria Luigia" Database OpenAIRE
2 results on '"Vigliotti, Maria Luigia"'

1. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

Author

Pellegrino Musto, Luca Laurenti, Angela Padula, Vittorio Simeon, Michele Gilio, Giovanni D'Arena, Marco Tucci, Giovanni Di Minno, Giacomo Loseto, Francesco Silvestris, Fiorella D'Auria, Sonya De Lorenzo, Anna Passarelli, Idanna Innocenti, Vincenzo De Feo, Matteo Nicola Dario Di Minno, Michele Cimminiello, Maria Luigia Vigliotti, D'Arena, Giovanni, Simeon, Vittorio, Laurenti, Luca, Cimminiello, Michele, Innocenti, Idanna, Gilio, Michele, Padula, Angela, Vigliotti, Maria Luigia, De Lorenzo, Sonya, Loseto, Giacomo, Passarelli, Anna, Di Minno, Matteo Nicola Dario, Tucci, Marco, De Feo, Vincenzo, D'Auria, Fiorella, Silvestris, Francesco, Di Minno, Giovanni, Musto, Pellegrino, DI MINNO, Matteo, and DI MINNO, Giovanni

Subjects
Male, rheumatoid arthritis, Cancer Research, Antineoplastic Agents, Immunological, 0302 clinical medicine, Risk Factors, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Infusions, Intravenous, Aged, 80 and over, CD20, biology, Hematology, Middle Aged, Prognosis, Oncology, Hematologic Neoplasms, 030220 oncology & carcinogenesis, Rheumatoid arthritis, Female, Rituximab, medicine.drug, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, adverse drug reaction, autoimmune disease, lymphoma, Young Adult, 03 medical and health sciences, Internal medicine, Pharmacovigilance, medicine, Humans, autoimmune diseases, pharmacovigilance, Aged, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Retrospective cohort study, medicine.disease, Discontinuation, Lymphoma, Settore MED/15 - MALATTIE DEL SANGUE, Immunology, biology.protein, business, Adverse drug reaction
Abstract

Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However, adverse drug reactions (ADRs) may occur after rituximab infusion, causing, in rare cases, its discontinuation. In this multicenter, retrospective study, among 374 patients treated with rituximab i.v., 23.5% experienced ADRs. Mean follow-up was 20.6 months (range 8-135). Overall, ADRs were significantly more frequent in non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemias (25-35.9%), than in autoimmune diseases (9.4-17.5%) (p

Published
2017

2. Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey

Author

D'Arena, G, Laurenti, L, Coscia, Cortelezzi, M, A, Chiarenza, A, Pozzato, G, Vigliotti, M, Nunziata, G, Fragasso, A, Villa, M, Grossi, A, Selleri, C, Deaglio, S, La Sala, A, DEL POETA, G, Simeon, V, Aliberti, L, De Martino, L, Giudice, A, Musto, P, De Feo, V, D'Arena, Giovanni, Laurenti, Luca, Coscia, Marta, Cortelezzi, Agostino, Chiarenza, Annalisa, Pozzato, Gabriele, Vigliotti, Maria Luigia, Nunziata, Giuseppe, Fragasso, Alberto, Villa, Maria Rosaria, Grossi, Alberto, Selleri, Carmine, Deaglio, Silvia, La Sala, Antonio, Del Poeta, Giovanni, Simeon, Vittorio, Aliberti, Luig, De Martino, Laura, Giudice, Aldo, Musto, Pellegrino, and De Feo, Vincenzo

Subjects
Adult, Complementary Therapies, Male, Cancer Research, medicine.medical_specialty, animal structures, Younger age, Chronic lymphocytic leukemia, Alternative medicine, MEDLINE, chronic lymphocytic leumia, therapy, Risk Factors, Internal medicine, Surveys and Questionnaires, Medicine, Humans, In patient, Aged, Neoplasm Staging, Aged, 80 and over, Geography, business.industry, leukemic progenitor cell, Cancer, Hematology, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Oncology, Italy, Health Care Surveys, Immunology, erythrocytes, Female, Lymphocyte, business, Settore MED/15 - Malattie del Sangue, CLL, Patient education
Abstract

Complementary and alternative medicine (CAM) is common in patients with cancer and its use is steadily increasing over time. We performed a multicenter survey in which the use of CAM in 442 Italian patients with chronic lymphocytic leukemia (CLL), the commonest form of leukemia in Western countries, was assessed. Data were collected by means of a face-to-face standardized questionnaire with several items. Mean age was 69 years; 258 patients (58%) were male and 184 (42%) female. Seventy-three patients (16.5%) were found to be CAM users. The most common CAM therapies were green tea, aloe formulations and high dose vitamins. Predictors of CAM use were female gender, younger age, higher education level, internet availability and newspaper reading. The reasons for CAM popularity among these patients are complex. Given the number of patients combining therapy with CAM and its possible drug interactions, doctor interest as well as patient education about CAM should be improved.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results